Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)

PURPOSE: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A. The objective of this study was to assess the long-term efficacy and safety (to week 156) of ixekizumab in patients with active psoriatic arthritis and inadequate response or intolerance to one or tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Orbai, Ana-Maria, Gratacós, Jordi, Turkiewicz, Anthony, Hall, Stephen, Dokoupilova, Eva, Combe, Bernard, Nash, Peter, Gallo, Gaia, Bertram, Clinton C., Gellett, Amanda M., Sprabery, Aubrey Trevelin, Birt, Julie, Macpherson, Lisa, Geneus, Vladimir J., Constantin, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991062/
https://www.ncbi.nlm.nih.gov/pubmed/33278016
http://dx.doi.org/10.1007/s40744-020-00261-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991062/
https://www.ncbi.nlm.nih.gov/pubmed/33278016
http://dx.doi.org/10.1007/s40744-020-00261-0

Ejemplares similares